drugset / Trial / NCT00919490

A Study of Single Dose of ABT-333 in Healthy Male Adults

NCT00919490

Phase 1 Completed 39 enrolled Abbott Abbott Japan Co.,Ltd · collab
RandomizedSingle-groupDouble-blindTreatment

Summary

The objectives of this study is to assess the safety, tolerability, and pharmacokinetics of blind, escalating, single, oral doses of ABT-333 under nonfasting conditions in healthy male adult in Japan.

Timeline

Start
2009-06
Primary completion
2009-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject dasabuvir Small molecule 400 mg Oral
Subject dasabuvir Small molecule 800 mg Oral
Subject dasabuvir Small molecule 1200 mg Oral
Subject dasabuvir Small molecule 1600 mg Oral